Canadian HIV vaccine shows promising results in early trials
"We have proven that there is no safety concern of SAV001-H in human administration and we are now prepared to take the next steps towards Phase II and Phase III clinical trials," said lead researcher Dong Joon Kim. "We are delighted to be one step closer to the first commercialized HIV vaccine."
According to Toronto news source TheStar.com, the SAV001-H vaccine is the only one being developed in Canada and among more than 30 being tested in human clinical trials. The vaccine is made with a unique design that includes a killed whole HIV-1 virus that aims to activate a patient's immune response. This same method has been used to develop vaccines for polio, rabies and influenza.
The vaccine has just completed Phase I, which is designed to see if it is safe to administer to humans. In the future, it will go through Phase II, which requires testing on 600 HIV-negative volunteers who are at high risk of infection. In Phase III, this sample size will balloon to 6,000 patients. If all goes well, the vaccine could be on the market in five years and could make a major difference in HIV rates around the world.